UK Adds Antidepressant Suicide and PSSD Warnings as CCHR Presses FDA to Match Them

The United Kingdom's Medicines and Healthcare products Regulatory Agency has announced new antidepressant safety measures for all patients, and a U.S. mental health industry watchdog is pointing to the move as evidence that American regulators are lagging behind their British counterparts. The changes, which follow a review prompted by concerns from patients and families, require clearer suicide-risk information for patients of all ages, a warning currently limited in the U.S. to children and young adults. For the first time, the UK measures also recognize Post-SSRI Sexual Dysfunction from certain antidepressants, a condition that can continue even after the drugs are stopped.

Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, says the MHRA has once again acted before the U.S. Food and Drug Administration and is calling on the FDA to issue equivalent warnings. The significance for Texas employers, insurers, and healthcare providers is direct: antidepressants are among the most widely prescribed medications in the country, and labeling differences between the UK and the U.S. shape how patients and their families weigh treatment decisions.

The UK regulator is adding "Post SSRI Sexual Dysfunction" to patient information leaflets for citalopram, escitalopram, duloxetine, fluvoxamine, fluoxetine, paroxetine, sertraline, venlafaxine, amitriptyline, and nortriptyline. Listed symptoms include genital numbness, loss of libido, erectile dysfunction, and difficulty reaching orgasm. In the UK, healthcare professionals must now discuss suicide risk and persistent sexual dysfunction when starting antidepressants, changing doses, or reviewing treatment, and patient leaflets will be updated with boxed warnings to make the risks more prominent. "Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions," said Dr. Alison Cave, chief safety officer at the MHRA.

CCHR traces a long history of regulatory divergence. In December 2003, the MHRA was first to warn that SSRI antidepressants increased suicide and self-harm risk in young people, a warning prompted by Dr. David Healy, professor of psychiatry at Bangor University. The FDA added a black-box warning for suicidal ideation in those 18 and younger in October 2004, later extended to age 24, leaving the implication that the risk ends on a person's 25th birthday. Healy warned in 2009 that antidepressants pose a suicide risk in all age groups, citing elevated relative risks for completed suicide in ages 18-64 based on FDA trial data.

The scale of exposure is substantial. According to the IQVia Total Patient Tracker Database for 2020, 45,204,771 Americans were taking antidepressants, including 2,154,118 in the 0-17 age group. Other regulators have moved as well: the European Medicines Agency adopted product information updates in 2019 warning of long-lasting sexual dysfunction, and Health Canada completed a safety review and announced labeling updates in 2021. CCHR urges the FDA to align U.S. labeling and patient information with the MHRA's updated measures, arguing that clear, prominent warnings on suicide risk for all ages and on persistent sexual dysfunction would give American patients and families the same information already provided in the UK and Europe. Until the FDA acts, the organization contends, millions of people taking these drugs remain without the full safety disclosures now required elsewhere.